Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EPS (Weighted Average and Diluted): 2009-2024

Historic EPS (Weighted Average and Diluted) for Myriad Genetics (MYGN) over the last 16 years, with Dec 2024 value amounting to -$1.41.

  • Myriad Genetics' EPS (Weighted Average and Diluted) fell 20.83% to -$0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.33, marking a year-over-year decrease of 238.37%. This contributed to the annual value of -$1.41 for FY2024, which is 55.66% up from last year.
  • Per Myriad Genetics' latest filing, its EPS (Weighted Average and Diluted) stood at -$1.41 for FY2024, which was up 55.66% from -$3.18 recorded in FY2023.
  • Myriad Genetics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.35 during FY2021, with a 5-year trough of -$3.18 in FY2023.
  • Over the past 3 years, Myriad Genetics' median EPS (Weighted Average and Diluted) value was -$1.41 (recorded in 2024), while the average stood at -$1.99.
  • Per our database at Business Quant, Myriad Genetics' EPS (Weighted Average and Diluted) crashed by 4,583.33% in 2020 and then skyrocketed by 88.29% in 2021.
  • Over the past 5 years, Myriad Genetics' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.69 in 2020, then reached -$2.99 in 2020, then soared by 88.29% to -$0.35 in 2021, then crashed by 297.14% to -$1.39 in 2022, then plummeted by 128.78% to -$3.18 in 2023, then surged by 55.66% to -$1.41 in 2024.